Literature DB >> 34887568

Exploratory results from the CheckMate 214 trial.

Maria Chiara Masone1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34887568     DOI： 10.1038/s41585-021-00553-2

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma.

Authors:  Jens Bedke; Laurence Albiges; Umberto Capitanio; Rachel H Giles; Milan Hora; Thomas B Lam; Börje Ljungberg; Lorenzo Marconi; Tobias Klatte; Alessandro Volpe; Yasmin Abu-Ghanem; Saeed Dabestani; Sergio Fernández-Pello; Fabian Hofmann; Teele Kuusk; Rana Tahbaz; Thomas Powles; Axel Bex
Journal:  Eur Urol       Date:  2021-12-15       Impact factor: 20.096
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.